These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 7580021)

  • 1. Use of buserelin and low-dose human menopausal gonadotropin for in vitro fertilization in women at risk of ovarian hyperstimulation syndrome.
    Wada I; Matson PL; Troup SA; Lieberman BA
    J Assist Reprod Genet; 1995 Apr; 12(4):252-7. PubMed ID: 7580021
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical pregnancy rates in an IVF program. Use of the flare-up protocol after failure with long regimens of GnRH-a.
    Karacan M; Erkan H; Karabulut O; Sarikamiş B; Camlibel T; Benhabib M
    J Reprod Med; 2001 May; 46(5):485-9. PubMed ID: 11396377
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of two gonadotropin-releasing hormone (GnRH) analogues (leuprolide and buserelin) in short and long protocols for assisted reproduction techniques.
    Tarlatzis BC; Grimbizis G; Pournaropoulos F; Bontis J; Lagos S; Pados G; Mantalenakis S
    J Assist Reprod Genet; 1994 Feb; 11(2):85-91. PubMed ID: 7819707
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of GnRH analog for induction of the ovulatory surge of gonadotropins in patients at risk of the ovarian hyperstimulation syndrome.
    Kulikowski M; Wołczyński S; Kuczyński W; Grochowski D; Szamatowicz M
    Gynecol Endocrinol; 1995 Jun; 9(2):97-102. PubMed ID: 7502696
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dual suppression with oral contraceptives and gonadotrophin releasing-hormone agonists improves in-vitro fertilization outcome in high responder patients.
    Damario MA; Barmat L; Liu HC; Davis OK; Rosenwaks Z
    Hum Reprod; 1997 Nov; 12(11):2359-65. PubMed ID: 9436663
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is continuation of a gonadotrophin-releasing hormone agonist (GnRHa) necessary for women at risk of developing the ovarian hyperstimulation syndrome?
    Wada I; Matson PL; Horne G; Buck P; Lieberman BA
    Hum Reprod; 1992 Sep; 7(8):1090-3. PubMed ID: 1400932
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ovarian hyperstimulation for in vitro fertilization preceded by prolonged administration of a gonadotropin-releasing hormone agonist.
    Tanbo T; Dale PO; Abyholm T
    Acta Obstet Gynecol Scand; 1990; 69(4):333-7. PubMed ID: 2123069
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effects of low-dose human chorionic gonadotropin combined with human menopausal gonadotropin protocol on women with hypogonadotropic hypogonadism undergoing ovarian stimulation for in vitro fertilization.
    Jiang S; Kuang Y
    Clin Endocrinol (Oxf); 2018 Jan; 88(1):77-87. PubMed ID: 28960429
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparisons of different dosages of gonadotropin-releasing hormone (GnRH) antagonist, short-acting form and single, half-dose, long-acting form of GnRH agonist during controlled ovarian hyperstimulation and in vitro fertilization.
    Hsieh YY; Chang CC; Tsai HD
    Taiwan J Obstet Gynecol; 2008 Mar; 47(1):66-74. PubMed ID: 18400585
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Severe early ovarian hyperstimulation syndrome following GnRH agonist trigger with the addition of 1500 IU hCG.
    Seyhan A; Ata B; Polat M; Son WY; Yarali H; Dahan MH
    Hum Reprod; 2013 Sep; 28(9):2522-8. PubMed ID: 23633553
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Comparison of GnRH antagonist fixed protocol and GnRH agonists long protocol in infertile patients with normal ovarian reserve function in their first in vitro fertilization-embryo transfer cycle].
    Yang S; Chen XN; Qiao J; Liu P; Li R; Chen GA; Ma CH
    Zhonghua Fu Chan Ke Za Zhi; 2012 Apr; 47(4):245-9. PubMed ID: 22781108
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The results of an in vitro fertilization program: two regimens of superovulation.
    Grochowski D; Wołczyński S; Kuczyński W; Kulikowski M; Szamatowicz M
    Gynecol Endocrinol; 1995 Mar; 9(1):59-62. PubMed ID: 7793301
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Increased incidence of ovarian hyperstimulation syndrome following combined GnRH agonist/hMG therapy].
    Lindner C; Braendle W; Köhler S; Bettendorf G
    Geburtshilfe Frauenheilkd; 1989 Apr; 49(4):337-44. PubMed ID: 2525500
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outcome of ovarian response after suppression with a gonadotropin releasing hormone agonist in different chronological periods prior to gonadotropin stimulation for in vitro fertilization.
    Loutradis D; Kallianidis K; Sakellaropoulos G; Dokos J; Siskos K; Creatsas G; Deligeoroglou E; Michalas S; Aravantinos D
    Gynecol Obstet Invest; 1991; 32(2):68-71. PubMed ID: 1748325
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of serum follicle stimulating hormone to luteinizing hormone ratio during buserelin acetate-induced pituitary desensitization on ovarian response to exogenous gonadotrophins in an in-vitro fertilization and embryo transfer programme.
    Yamashita T; Ishimaru T; Fujishita A; Kawano M; Yamabe T
    Hum Reprod; 1996 Aug; 11(8):1615-9. PubMed ID: 8921103
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intranasal nafarelin versus buserelin (short protocol) for controlled ovarian hyperstimulation before in vitro fertilization: a prospective clinical trial.
    Avrech OM; Goldman GA; Pinkas H; Amit S; Neri A; Zukerman Z; Ovadia J; Fisch B
    Gynecol Endocrinol; 1996 Jun; 10(3):165-70. PubMed ID: 8862491
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Consistent high clinical pregnancy rates and low ovarian hyperstimulation syndrome rates in high-risk patients after GnRH agonist triggering and modified luteal support: a retrospective multicentre study.
    Iliodromiti S; Blockeel C; Tremellen KP; Fleming R; Tournaye H; Humaidan P; Nelson SM
    Hum Reprod; 2013 Sep; 28(9):2529-36. PubMed ID: 23873146
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The prevention of ovarian hyperstimulation syndrome.
    Corbett S; Shmorgun D; Claman P; ;
    J Obstet Gynaecol Can; 2014 Nov; 36(11):1024-1033. PubMed ID: 25574681
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 450 IU versus 600 IU gonadotropin for controlled ovarian stimulation in poor responders: a randomized controlled trial.
    Lefebvre J; Antaki R; Kadoch IJ; Dean NL; Sylvestre C; Bissonnette F; Benoit J; Ménard S; Lapensée L
    Fertil Steril; 2015 Dec; 104(6):1419-25. PubMed ID: 26361207
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Coasting: a response to excessive ovarian stimulation].
    Dechaud H; Anahory T; Aligier N; Arnal F; Humeau C; Hédon B
    Gynecol Obstet Fertil; 2000 Feb; 28(2):115-9. PubMed ID: 10758585
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.